模拟临床检测在头颈癌诊断液体相生物标志物验证中的范围综述
约3%的研究使用了至少一种模拟检测方法,仅蛋白质、mRNA和代谢组标志物曾用这些方法验证;同时使用两种方法的研究在QUADAS-2工具上偏倚担忧更低。
要点
- 约3%的头颈癌生物标志物验证研究使用了模拟检测方法。
- 仅蛋白质、mRNA和代谢组标志物曾用模拟检测方法验证。
- 同时使用两种方法的研究在QUADAS-2上偏倚担忧更低。
核心结论
- 在初步建立分类准确性后,验证头颈癌诊断生物标志物的研究需要纳入模拟检测方案。
研究设计与样本
- 范围综述,电子数据库检索2009年1月1日至2020年8月1日发表的英文研究。
主要发现
- 约3%的研究使用了至少一种模拟检测方法进行生物标志物验证。
- 蛋白质、mRNA和代谢组标志物是唯一曾用这些方法尝试验证的标志物类别。
- 同时使用两种方法的研究在QUADAS-2工具上偏倚担忧更低。
临床怎么用
- 在头颈癌诊断生物标志物验证中,可考虑采用前瞻性采样和盲法等模拟检测方案以降低偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review sought to determine the range and nature of prospective-sampling and blinding methods for validating nonviral biofluid markers diagnostic of head and neck carcinomas. Electronic database searching was conducted to identify studies published in English from January 1, 2009 to August 1, 2020. Sixteen studies from 17 articles published between 2011 and 2020 were included in this review. We found that about 3 out of 100 studies utilized at least one of the mock testing approaches for biomarker validation. Protein, mRNA, and metabolomic markers also represented the only groups whose validation has been attempted using these methods. Furthermore, studies that utilized both methods were found to have lower bias concerns on the quality assessment of diagnostic accuracy studies (QUADAS-2) tool. Overall, there is a need to include these protocols in research endeavours verifying diagnostic biomarkers for head and neck carcinomas following the preliminary establishment of their classification accuracy.
引用
- Adeoye J, Wan CCJ, Thomson P, et al. Mock clinical testing in the validation of fluid-phase biomarkers for head and neck carcinoma diagnosis: Scoping review. Head Neck. 2020. PMID: 33151603. doi:10.1002/hed.26526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。